Summary of China Pharma and Biotech Conference Call Industry Overview - The China healthcare sector is experiencing its strongest rally since mid-2023, with the Hang Seng Biotech and MSCI China Healthcare indices showing year-to-date (YTD) returns of 57% and 38%, respectively, outperforming broader indices like Hang Seng and MSCI China at 20% and 16% [1][10] - The current market is at 30% of the peak seen during the last healthcare boom in 2020-2021, with a notable shift towards mature companies and top players rather than early-stage firms [1][2] - Public financing has surged, increasing 4 times in 1H25 compared to 1H24, with about two-thirds of IPO and follow-on offerings yielding positive returns [1][12] Market Valuation and Opportunities - Valuations in the China healthcare sector are now at or above global counterparts, with MSCI China healthcare P/S ratios crossing over with S&P 500 healthcare [2] - Individual stock performance varies significantly, with funds showing interest in companies with lower valuation multiples and potential for out-licensing deals [2][52] - Specific companies like CSPC are considered overheated with a PEG ratio of 14.5x, while Hengrui (2.3x) and Sino Biopharm (2.0x) are viewed as cheaper alternatives [3][44] Biotech Sector Insights - Biotech companies are valued based on market cap to projected 2032 revenue, ranging from 2-5x. Companies like BeiGene (2.7x) and Zai Lab (1.2x) are seen as undervalued, while Akeso (4.7x) and Kelun Biotech (5.6x) are considered relatively pricey [4][48] - The biotech sector has seen a significant increase in market capitalization, rising from US$102 billion to US$160 billion YTD 2025 [11] Clinical Trials and R&D - The number of clinical trial starts in China has shown consistent growth, with local assets making up over 50% of the global pipelines for the first time in 2025 [1][33] - Innovative drug modalities, particularly in oncology, have seen a resurgence in clinical trials, indicating sustained R&D efforts despite previous market downturns [32][36] Out-licensing Trends - There has been a boom in outbound licensing deals, with companies like RemeGen and Innovent leading the way. This trend is expected to continue, although there are concerns about saturation in certain drug classes [34][52] - The out-licensing model has remained resilient against geopolitical challenges, with no significant shifts in FDA attitudes towards China-originated drugs [34] Investment Implications - The report rates Akeso, Hansoh, Innovent, and Hengrui as Outperform, while BeiGene, CSPC, Sino Biopharm, and Zai Lab are rated as Market-Perform [7] - A methodological shift in valuation is noted, with increased emphasis on multiple-based valuation for mature companies, while biotechs will continue to use P/S and DCF models [8] Conclusion - The China pharma and biotech sector is on an upward trajectory, driven by strong market sentiment, increased public financing, and a robust pipeline of clinical trials. However, caution is advised regarding valuation levels and the sustainability of the current rally, particularly in the context of out-licensing deals and market saturation [52][53]

Investment Rating - The report rates Innovent shares as "Buy" with a target price raised to HK$90 from HK$60, indicating an expected share price return of 16.4% [5][18]. Core Insights - Innovent is leading the development of next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) combinations, which are expected to provide broader-spectrum, highly-potent, and less-toxic cancer treatments [9][18]. - The key product IBI363 has shown promising data in various cancers, including non-small cell lung cancer (NSCLC) and mucosal/acral melanoma, positioning it as a cornerstone for next-generation IO therapy [2][10]. - Innovent aims to achieve Rmb20 billion in product revenue by 2027 and advance five pipeline assets into global multi-regional clinical trials by 2030 [1][3]. Financial Projections - Revenue forecasts for 2025, 2026, and 2027 have been fine-tuned by 1%, 2%, and 2% respectively, with expected earnings per share (EPS) of Rmb0.05, Rmb0.53, and Rmb1.22 [3]. - Innovent's revenue is projected to grow from Rmb9.4 billion in 2024 to Rmb16.6 billion by 2027, reflecting a compound annual growth rate (CAGR) of approximately 23.1% [4][8]. Clinical Development - IBI363 is currently undergoing registrational trials for various indications, including head-to-head trials against pembrolizumab for melanoma and NSCLC, with enrollment expected to complete by the end of 2025 [2][12]. - Innovent is also developing multiple ADC platforms, including SyntecanE, SoloTx, and DuetTx, which are designed to enhance efficacy and reduce toxicity in cancer treatments [11][12]. Market Position - Innovent has transformed from a biotech start-up to a leading biopharma company with 15 launched commercial products, showcasing strong R&D and commercialization capabilities [17][18]. - The company is positioned to leverage its dedicated R&D platform, Innovent Academy, which employs over 500 scientists focused on developing innovative cancer therapies [9][18].

Investment Rating - The report maintains an "Overweight" (OW) rating for several sectors including Communication Services, Consumer Discretionary, Financials, Healthcare, and Industrials, while underweighting (UW) Energy and Utilities [7][11]. Core Insights - The report anticipates a range-bound MXCN (70-80) in the near term with potential upside in the second half of 2025, driven by factors such as strong southbound inflows into Hong Kong and a possible resolution in US-China trade negotiations [6][22]. - The forecast for MXCN/CSI300 is projected to reach HK$80/Rmb4,150 (+5.1%/5.8% from the previous close) in the base case and HK$89/Rmb4,420 (+16.8%/12.7% from the previous close) in the upside case by the end of 2025 [6][22]. - The report highlights a shift in consumer preferences from "affordable treats" to "affordable experiences," indicating a potential investment opportunity in sectors related to learning and at-home entertainment [6][8]. Summary by Sections Key Drivers for 2H25 - The report identifies key drivers for the second half of 2025, including a rebound in GDP growth and a rise in the share of sub-sectors in Recovery and Expansion [17][20]. - The business cycle profile of China equity is noted to have troughed in 3Q24, with a significant increase in the number of sectors showing recovery [17][20]. Earnings Outlook & Sector Weights - The report predicts upside for MXCN EPS compared to consensus, while forecasting downside for CSI300/CSI500/CSI1000 EPS growth due to differing sector exposures [6][7]. - Sector weights indicate a return to an Overweight stance on IT, while maintaining Overweight on Communications Services, Discretionary, Healthcare, and Materials [6][7]. Thematic Stock Screens - The report emphasizes several themes, including the rise of high yielders favored by onshore investors and the potential for financial sector consolidation [6][11]. - Top picks for 2H25 include Tencent, Alibaba, and Innovent, among others, reflecting a focus on companies with strong growth potential and favorable market conditions [6][7][11].

Investment Rating - The report suggests an "Overweight" rating for sectors benefiting from the influx of educated youth into the workforce, particularly in services, healthcare, financial services, high-tech industries, and hospitality & entertainment [66][69]. Core Insights - Youth unemployment in China has increased significantly, from approximately 10% in 2018 to around 21% in the summer of 2023, but this is viewed as an opportunity rather than a threat due to the unprecedented level of education among the youth entering the workforce [2][5][6]. - China is transitioning from an industrial policy-driven economy to a services-oriented economy, with a notable increase in the contribution of services to GDP, which has risen from 32% in 1990 to 55% in 2023 [4][53]. - The report highlights that the most educated cohort in China's history is entering the labor market, with tertiary education enrollment rates soaring from 3% in 1990 to 75% in 2023, indicating a well-prepared workforce [4][14][10]. Summary by Sections Youth Unemployment - Youth unemployment is currently misinterpreted as a threat, while it actually presents an opportunity for economic growth as the most educated population enters the workforce [6][13]. - The report emphasizes that the rise in youth unemployment should be viewed through the lens of potential service consumption growth [6][20]. Human Capital Development - China has rapidly upskilled its population, with 15,467 per 100,000 now holding a degree, a fourfold increase over the past 20 years [4][10]. - Investment in education has increased from 2.4% of GDP in 2005 to 4.0% in 2022, leading to a significant rise in STEM graduates [4][39]. Service Sector Growth - The services sector in China is expected to grow significantly, with the potential to reach levels comparable to the US, where services contribute 76% to GDP [53][55]. - Key sectors identified for growth include healthcare, financial services, high-tech industries, and hospitality & entertainment, which currently employ a lower percentage of the labor force compared to the US [62][66]. Investment Opportunities - The report lists specific companies that are well-positioned to benefit from the growth in service consumption, including Trip.com, MGM China, NetEase, and Ping An Group, among others [66][69][88]. - The financial intermediation sector is highlighted as having substantial growth potential, particularly in health and protection products, with a noted lack of active CPAs in China compared to the US [70][69]. Healthcare Sector - The healthcare sector is poised for growth, with China now holding a 20% share of global PCT patent publications in biotechnology, second only to the US [76][81]. - The report identifies companies like Innovent and Akeso as potential beneficiaries of the expanding healthcare services market [76][81].

Summary of China Pharma and Biotech Conference Call Industry Overview - The focus is on the **China Pharma and Biotech** sector, particularly the out-licensing activities and their sustainability in 2025 [1][7]. Key Insights - **Out-licensing Growth**: As of June 17, 2025, the total value of China's out-licensing deals reached **$54 billion**, surpassing the **$47 billion** total for the entire year of 2024. This indicates a significant increase in deal-making activity [1][9]. - **US-bound Deals**: Historically, about half of China's licensing deals have been with US partners. In 2025, **57%** of the deal value is attributed to US-bound deals, suggesting that geopolitical tensions have not significantly impacted these transactions [1][9][11]. - **Global Licensing Trends**: The total value of global license transfers has been steadily increasing, with a notable contribution from China. In 2025, China's outbound deal value exceeded that of developed markets for the first time [2][13][15]. Emerging Drug Classes - **New Favorites**: The PD-1/VEGF bispecific and GLP-1 drug classes have emerged as the new favorites in out-licensing, with the former attracting deals worth over **$20 billion** and upfront payments exceeding **$3 billion** [4][38]. - **Historical Context**: Previous booms in 2020-2021 were primarily driven by PD-1 and TIGIT drugs, which ultimately faced saturation and deal terminations. The current growth drivers may also face similar risks of overheating and saturation [3][5][39]. Market Dynamics - **R&D Efficiency**: China's R&D efficiency has improved significantly, with clinical trial costs being approximately **1/5** of those in the US. This has led to a substantial increase in the size and quality of local players' pipelines [7]. - **Investment in R&D**: Despite market challenges, top pharma and biotech players in China continue to invest heavily in R&D, leading to a growing number of first-in-class assets [7]. Deal Activity - **Mega-deals**: There have been **23 license transfers** to global players with total deal values exceeding **$500 million**, with over **two-thirds** of these deals valued at **$1 billion or more** [8][9]. - **Upfront Payments**: The average upfront payment for China's outbound deals is lower than that of developed markets, with a typical range of **3-5%** of total deal value compared to around **10%** in developed markets [2][14]. Future Outlook - **Cautious Optimism**: While long-term growth in out-licensing is expected, there are short-term concerns regarding the sustainability of the current boom, particularly with the potential saturation of key drug classes [5][39]. - **Market Share Potential**: Despite the significant role of top 20 multinational corporations (MNCs) in China's out-licensing deals, China's share of these MNCs' licensing deals remains low, indicating potential for market share gains [44][50]. Conclusion - The China Pharma and Biotech sector is experiencing unprecedented growth in out-licensing activities, driven by improved R&D efficiency and strategic partnerships, particularly with US firms. However, the sustainability of this growth remains a concern as the market evolves and potential saturation looms for key drug classes.

Investment Rating - The report indicates a cautious outlook for the A-share market, suggesting a barbell strategy with micro-cap and bank stocks performing steadily [6][10]. Core Insights - The A-share market has remained flat amid Middle East tensions, supported by the Lujiazui Forum, while H-shares lagged due to increased risk-off sentiment [1]. - Biotech and New Consumption sectors in Hong Kong have seen a sharp pullback after significant gains of 30-50% YTD, with the HS Biotech Index dropping over 9% in the past five days [2][3]. - The Lujiazui Forum has announced measures to support Shanghai as a global financial center, including the reopening of IPOs for unprofitable tech firms under new standards [10][11]. Summary by Sections A-share Market - The A-share market is experiencing a barbell strategy with micro-cap and bank stocks outperforming, while foreign participation remains light [6]. - Limited liquidity is driving small-cap beta, while deflationary pressures keep dividend plays attractive [7][8]. Hong Kong Market - The biotech and new consumption sectors have both declined after strong rallies, with notable sell-offs in stocks like CSPC and Innovent [2][3]. - The new consumption sector has seen significant drops in stocks such as PopMart and Laopu, attributed to profit-taking rather than clear negative catalysts [4]. Lujiazui Forum Insights - The forum emphasized credibility and global financial connections, with discussions on reopening IPOs for unprofitable tech firms and expanding QFII investment scope [10][12]. - AI and semiconductor companies are likely to be prioritized for new listings, with stocks in the growth tier marked with a "U" label to indicate investment risk [11]. Macro Economic Context - Retail sales showed strong performance in May, but sustainability is questioned due to potential payback effects in June [13]. - Property prices in 70 cities have continued to decline, with secondary market data indicating a drop of 5-15% over the past year [14]. Investor Behavior - Overall A-share flows indicate a selling trend, with long-only and hedge funds both showing net selling behavior despite the geopolitical tensions [18]. - Specific sectors like AI infrastructure are seeing renewed interest, with notable buying in companies like Zhongji Innolight and Eoptolink [17].

Summary of Key Points from the Conference Call Industry Overview - The report focuses on the **biopharmaceutical sector in China**, highlighting its resurgence driven by innovation and increased deal activity with multinational corporations (MNCs) [1][2]. Core Insights - **Global Competitiveness**: China's pharma sector is confirmed to be globally competitive, with significant partnerships such as Summit Therapeutics' licensing agreement with Akeso for ivonescimab (up to $5 billion) and Pfizer's deal with 3SBio for SSGJ-707 (up to $6 billion) [2]. - **Investment in Obesity Treatments**: Companies are investing in the obesity treatment space, with notable deals including Merck's $1.9 billion agreement with Hansoh Pharma and Novo's $2 billion deal with United Bio-Technology [2]. - **Long-Term Winners**: AstraZeneca (AZN) and Sanofi (SAN) are identified as long-term winners in the region, with both companies actively investing and expanding their R&D presence in China [7][11]. R&D and Business Development Opportunities - **Rapid R&D Advancement**: China's biopharma industry is shifting from generics to genuine innovation, with improved R&D efficiency and lower costs [8][41]. - **Rich Pipeline of Assets**: MNCs are increasingly seeking business development (BD) deals in China, with a wealth of attractive pipeline assets available for international partnerships [9]. - **Key Asset Types**: Bispecific antibodies, GLP-1 therapies, and antibody-drug conjugates (ADCs) are highlighted as prominent areas for BD opportunities [10][65]. Market Dynamics - **Market Share Growth**: The share of innovative drugs in China's core hospital pharmaceutical market increased from 21% in 2015 to 29% in 2024, with local companies' share rising from 18.7% to 27.8% [24][25]. - **Declining Contribution**: There is a modest decline in China sales as a percentage of global sales among large-cap EU pharma companies, with AstraZeneca's share dropping from 20% in 2020 to an estimated 12% in 2024 [29][31]. Strategic Collaborations - **M&A Activity**: The report notes a boom in M&A activity as companies seek to acquire innovative pipeline assets amid global pricing pressures and patent expirations [40]. - **Emerging Global Innovation Hub**: China is becoming a global hub for innovative drug R&D, with a significant increase in out-licensing deals, reaching a total value of $50.8 billion in 2024 [40][48]. Specific Therapeutic Areas - **Bispecific Antibodies**: The report emphasizes the growing interest in bispecific antibodies, particularly those targeting PD-1/VEGF pathways, with significant licensing deals indicating global confidence in these assets [66][68]. - **GLP-1 Therapies**: The report outlines the evolution of GLP-1 therapies, with a focus on long-acting formulations and oral small molecules, highlighting numerous ongoing clinical trials and licensing deals [70][72]. - **Antibody-Drug Conjugates (ADCs)**: China is emerging as a leader in ADC innovation, with approximately 40% of the global ADC pipeline originating from China and a significant increase in international licensing transactions [77][78]. Conclusion - The biopharmaceutical sector in China is positioned for growth, with strong R&D capabilities, a rich pipeline of innovative assets, and increasing global interest from MNCs. Companies like AstraZeneca and Sanofi are well-positioned to capitalize on these opportunities, while the landscape for innovative therapies continues to evolve rapidly.

Investment Rating - The report does not explicitly state an investment rating for the industry or specific companies involved in the ADA 2025 meeting presentations [2]. Core Insights - The upcoming American Diabetes Association (ADA) meeting is expected to showcase significant presentations from Chinese pharmaceutical companies, particularly focusing on diabetes and obesity treatments [1][3]. - Innovent is anticipated to present data on its Phase 3 study of Mazdutide for Type 2 Diabetes (T2D) and preclinical data for a multi-target candidate involving GLP-1, GIP, GCG, and PCSK9 [1][3]. - There is a growing interest from large pharmaceutical companies in the obesity treatment space, suggesting potential for increased collaborations following the generation of more clinical data [1]. Summary by Sections Presentations at ADA 2025 - Innovent will present the DREAMS-1 Phase 3 study results for Mazdutide and preclinical data for a novel antibody-peptide conjugate targeting multiple receptors [3]. - Huadong will showcase a Phase I study of HDM1005, a dual GLP-1/GIP receptor agonist, focusing on safety and tolerability [3]. - Sciwind Biosciences is set to present data on Ecnoglutide, a GLP-1 analog for obesity, in a Phase 3 study [3]. - HighTide will present findings from a Phase 3 study of HTD1801, a berberine-based treatment for T2D [3]. - BrightGene Bio-Medical will discuss a Phase 2 trial of BGM0504, a GIPR/GLP-1R dual agonist for T2D [3]. Poster Sessions - Huadong will present a Phase 1b study of HDM1002 for obesity, targeting Activin Type II receptors [4]. - Laekna will showcase monoclonal antibodies LAE102, LAE103, and LAE123 as candidate therapeutics for muscle growth and fat reduction [4]. - Guanadona will present data on RAY1225, a GIPR/GLP-1R agonist, in studies for both obesity and T2D [4].

Investment Rating - The report indicates a positive outlook for the China healthcare sector, with a recovery underway and improving investor sentiment, particularly in the biotech segment, which has seen a year-to-date performance increase of 37% [1]. Core Insights - The report highlights a significant recovery in the China healthcare sector, driven by improving investor sentiment and bottoming valuations, with offshore healthcare stocks up 21% year-to-date [1]. - Biotech companies are expected to benefit from licensing-out themes and resilience to geopolitical uncertainties, with key events like ASCO in June serving as potential catalysts for individual stock performance [1]. - There is a growing interest in domestic demand, particularly in capital expenditures and hospital traffic, with robust equipment tendering observed [1]. - The report anticipates a consumption recovery in areas such as refractive surgeries and orthodontics, although the sustainability of this recovery is contingent on the broader macroeconomic outlook [6]. - The report emphasizes the importance of global collaboration and licensing opportunities for pharmaceutical companies, with a focus on upcoming data releases at ASCO to enhance business development visibility [16]. Summary by Relevant Sections Biotech - The biotech sector is focusing on global licensing deals and achieving break-even points, with significant catalysts expected from the upcoming ASCO conference [13][14]. - Companies like Zai Lab and Innovent are highlighted for their innovative drug pipelines and potential for global collaboration [14][15]. Pharma - The pharmaceutical industry experienced soft growth in Q1 2025, but companies with strong product cycles, such as Hengrui, are showing better earnings trends [16]. - Collaboration opportunities are expected to increase, particularly with data releases at ASCO [16]. CDMO - CDMO companies reported better-than-expected results in Q1 2025, with strong order growth and maintained guidance for FY25 [17]. - Companies like WuXi Apptec and Asymchem are noted for their resilience in earnings delivery [17]. Medical Consumables - The report indicates challenges in inpatient surgeries due to reimbursement controls, but opportunities exist in the obesity and GLP-1 segments [19]. - Surgical volumes are expected to remain challenging, with ongoing pricing pressures [19]. Capital Equipment - Strong tendering activity was noted, but pricing pressures from value-based purchasing (VBP) are leading to longer revenue realization timelines [21]. - Companies like United Imaging and Mindray are expected to see positive growth in the coming quarters [21]. Retail Pharmacy - The retail pharmacy sector is undergoing a market clearing process, with a net decrease in drugstores for the first time, indicating a consolidation trend [26]. - Yifeng is highlighted as a resilient player in this space, benefiting from operational efficiency [26].

Investment Rating - The report maintains a "Buy" rating for several healthcare stocks, including Wuxi Apptec and Eyebright, based on their strong growth potential and market positioning [11]. Core Insights - The EU's planned restrictions on Chinese medtech firms' access to public procurements over EUR 5 million are expected to have limited impact on the covered companies, as most do not participate in such procurements and have manageable revenue exposure to the EU market [3]. - The healthcare indices in China showed positive performance, with HSHCI rising by 4.1% and HSHKBIO by 4.5% during the week of June 2-6, 2025, indicating a favorable market trend [2]. - Recent approvals in the drug sector include Akeso's cadonilimab for cervical cancer and Hansoh's aumolertinib for NSCLC in the UK, showcasing ongoing innovation and regulatory progress in the industry [4][5]. Summary by Sections Market Access and Regulatory Environment - The EU's International Procurement Instrument investigation concluded that China has limited EU medical device producers' access to government contracts, leading to the proposed restrictions [3]. - Companies like Mindray and MGI Tech have established local manufacturing facilities, which may help mitigate the impact of these restrictions [3]. Drug Approvals and Developments - Akeso's cadonilimab received approval for treating first-line cervical cancer, while Innovent and Hutchmed's sintilimab + fruquintinib application was accepted for renal cell carcinoma [4]. - Hansoh's aumolertinib has been approved in the UK for specific NSCLC patients, indicating a strong pipeline for innovative therapies [4]. Stock Performance and Recommendations - The report highlights top picks in the healthcare sector, including Wuxi Apptec and Eyebright, based on their expected solid fundamental recovery and market share potential [11]. - The report notes that the chemicals sector outperformed healthcare indices, with a 1.7% increase in A shares and a 3.8% increase in H shares [12].